Abstract

Background Luteinizing hormone-releasing hormone LHRH agonist therapy is an androgen suppression therapy aimed to treat prostate cancer by means chemical castration Despite being frequently used in clinical setting there is no prior study examining the of LHRH agonist drugs in Indonesia This study aims to assess the efficacy of LHRH agonists in prostate cancer patients measured by the reduction of serum prostate specific antigen PSA three months following treatment Methods The study used retrospective observational cohort design upon medical record of 83 prostate cancer patients in GatotSoebroto Army Hospital Jakarta Indonesia We analyzed the recorded patients age TNM staging histologic grading LHRH agonists used in therapy along with the average baseline PSA level prior and three months following treatment Paired T-test Wilcoxon ANOVA and Kruskal-Wallis Test were used where appropriate Results We found significant change in PSA levels before and three-months following the use of LHRH agonists p 0 001 with the median decreasing from 56 20 4 24-7 445 00 to 7 08 0 01-942 00 Significant association was also found between PSA level prior to treatment and the prostate cancer groups according to stages p 0 001 histological grades p 0 020 and medications used p 0 010 However this study found no significance of these groups in the PSA level reduction three months after therapy